Table 3. Effect of clinical variables on individual genotypic polymorphisms in elevated risk of LAA stroke disease.
| Genotype | Hypercholesterolemia | Alcoholism | Heavy cigarette smoking | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Ca/Co | aOR (95% CI) a | Ca/Co | aOR (95% CI) | Ca/Co | aOR (95% CI) | ||||
| e-NOS G894T | |||||||||
| GG | Null | 74/99 | 1.00 (Ref)b | Null | 142/174 | 1.00 (Ref) | Null | 109/160 | 1.00 (Ref) |
| GG | Yes | 77/86 | 1.20 (0.78–1.84) | Yes | 9/11 | 1.01 (0.41–2.49) | Yes | 42/25 | 2.47 (1.42–4.28)** |
| GT/TT | Null | 37/41 | 1.21 (0.71–2.06) | Null | 60/48 | 1.53 (0.99–2.38) | Null | 47/45 | 1.53 (0.95–2.47) |
| GT/TT | Yes | 41/17 | 3.23 (1.70–6.12)*** | Yes | 18/10 | 2.21 (0.99–4.93) | Yes | 31/13 | 3.50 (1.75–6.99)*** |
| Cav-1 G14713A | |||||||||
| GG | Null | 70/100 | 1.00 (Ref) | Null | 120/161 | 1.00 (Ref) | Null | 96/150 | 1.00 (Ref) |
| GG | Yes | 68/74 | 1.31 (0.84–2.06) | Yes | 18/13 | 1.85 (0.88–3.94) | Yes | 42/24 | 2.73 (1.56–4.80)*** |
| GA/AA | Null | 41/40 | 1.47 (0.86–2.49) | Null | 82/61 | 1.80 (1.20–2.71)** | Null | 60/55 | 1.71 (1.09–2.66)* |
| GA/AA | Yes | 50/29 | 2.46 (1.42–4.27)** | Yes | 9/8 | 1.51 (0.57–4.03) | Yes | 31/14 | 3.46 (1.75–6.84)*** |
| Cav-1 T29107A | |||||||||
| TT | Null | 65/97 | 1.00 (Ref) | Null | 115/154 | 1.00 (Ref) | Null | 90/141 | 1.00 (Ref) |
| TT | Yes | 63/70 | 1.34 (0.85–2.13) | Yes | 13/13 | 1.34 (0.60–3.00) | Yes | 38/26 | 2.29 (1.30–4.03)** |
| TA/AA | Null | 46/43 | 1.60 (0.95–2.69) | Null | 87/68 | 1.71 (1.15–2.55)** | Null | 66/64 | 1.62 (1.05–2.49)* |
| TA/AA | Yes | 55/33 | 2.49 (1.46–4.24)** | Yes | 14/8 | 2.34 (0.95–5.77) | Yes | 35/12 | 4.57 (2.25–9.26)*** |
a aORs and 95% CIs were calculated in a logistic regression model after adjusting for age and gender of IS patients.
b Ref, represents the reference group, indicating 894GG in e-NOS as well as 14713GG and 29107TT in Cav-1, respectively.
* P < 0.05,
** P < 0.01 and
*** P < 0.001.